TG Therapeutics is betting that its MS drug BRIUMVI can win patients not just on results, but on convenience—especially if a self-injection version takes off as more care shifts to the home. The catch is that the company leans heavily on this one product while pricing pressure, regulators, and bigger rivals could slow that momentum.Read more
TG Therapeutics leans heavily on one main multiple-sclerosis drug, and growing pressure from insurers, regulators, and rival treatments could make it harder to keep prices and market share. At the same time, strong early demand plus efforts to broaden the drug’s use and add new formats could keep growth going—if the company can stay ahead of cost and competition.Read more
Key Takeaways The upcoming launch of subcutaneous BRIUMVI and expanded market access are set to drive substantial long-term revenue and sales growth. Strong commercial execution, demographic trends, and a lean operational model create pathways for ongoing market penetration and margin improvement.Read more
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
